Logo

Horizon BRAF-Resistant Melanoma PDX Models

May 26, 2017

Horizon Discovery has launched four new BRAF-resistant melanoma patient derived xenograft (PDX) models. The company has partnered with the Wistar Institute of Anatomy and Biology in Philadelphia to make their melanoma PDX models available to the research community. The models are created by implanting cancerous tissued from a human primary tumor directly into immunodeficient mouse or rat models.They can support drug efficacy studies, the company said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.